Search

Displaying results 8161 - 8170 of 10000 in total
  1. Drug

    Efdoralprin alfa

    go.drugbank.com/drugs/DB18384
    Investigational

    Efdoralprin alfa is a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein.[L54928] It is being investigated as a restorative therapy in adults with AATD emphysema.[L54928]

  2. Drug

    Fenvalerate

    go.drugbank.com/drugs/DB18391
    Experimental

    Synonyms: methyl (R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3- ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoateCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    AVB-101

    go.drugbank.com/drugs/DB18416
    Investigational

    AVB-101 is a recombinant AAV9 vector encoding the human progranulin (PGRN) gene.

  4. Drug

    tgAAG-76

    go.drugbank.com/drugs/DB18421
    Investigational

    tgAAG-76 consists of a recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65.

  5. Drug

    NFS-02

    go.drugbank.com/drugs/DB18422
    Investigational

    NFS-02 is a recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1).

  6. Drug

    ZVS101e

    go.drugbank.com/drugs/DB18424
    Investigational

    ZVS101e is a recombinant adeno-associated virus vector carrying human CYP4V2 gene.

  7. Drug

    RBIO-101

    go.drugbank.com/drugs/DB18425
    Experimental

    RBIO-101 is a recombinant adeno-associated virus vector encoding human CYP4V2 protein.

  8. Drug

    Vurolenatide

    go.drugbank.com/drugs/DB18440
    Investigational

    Vurolenatide is a recombinant fusion protein comprising exenatide and XTEN.

  9. Drug

    UV1

    go.drugbank.com/drugs/DB18470
    Experimental

    UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit

  10. Drug

    Emerfetamab

    go.drugbank.com/drugs/DB18474
    Investigational

    Emerfetamab is a bispecific T cell engager antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor.